Uterine fibroids (leiomyomata) affect up to 70% of women by age 50 and are the leading indication for hysterectomy worldwide. Their growth depends on a fundamental imbalance: fibroid smooth muscle cells proliferate but resist dying. FOXO1 — forkhead box protein O1¹¹ forkhead box protein O1
a transcription factor that drives expression of pro-apoptotic genes including BIM, PUMA, and Fas ligand — is a central regulator of that life-or-death balance. An intronic variant in FOXO1, rs7986407, has emerged from multiple genome-wide association studies as a locus influencing both uterine leiomyoma risk and the timing of natural menopause, two phenotypes that converge on estrogen exposure duration and uterine smooth muscle cell biology.

The Mechanism

Under normal conditions, FOXO1 translocates to the nucleus and transcribes genes that initiate programmed cell death — a key brake on abnormal cell accumulation. In leiomyoma cells, however, progestins (which drive fibroid growth) rapidly activate the PI3K/AKT signaling cascade²² PI3K/AKT signaling cascade
a pro-survival kinase pathway that is constitutively elevated in many tumors. Activated AKT phosphorylates FOXO1 at Ser256, causing it to be sequestered in the cytoplasm where it cannot reach its target genes. The result: pro-death signals are silenced and fibroid cells survive and accumulate. This mechanism was directly demonstrated by Hoekstra et al. (2009), who showed that blocking AKT or forcing nuclear FOXO1 entry with Psammaplysene A restored apoptosis in leiomyoma cells³³ blocking AKT or forcing nuclear FOXO1 entry with Psammaplysene A restored apoptosis in leiomyoma cells
Hoekstra AV et al. J Clin Endocrinol Metab 2009.

The rs7986407 variant is intronic and does not alter the FOXO1 protein sequence. Its functional effect likely operates through regulatory mechanisms — altered splicing efficiency, changes in intronic enhancer activity, or linkage disequilibrium with regulatory variants in the FOXO1 locus — that may modulate FOXO1 expression levels or transcript stability in uterine smooth muscle cells. The precise molecular consequence of the G allele in this tissue remains an open research question.

FOXO1 also plays a broader role in reproductive physiology: in ovarian granulosa cells, FOXO1 and its close family member FOXO3 regulate follicular development and granulosa cell apoptosis. Selective deletion of both in mice caused complete infertility⁴⁴ caused complete infertility
Liu Z et al. Mol Endocrinol 2015, demonstrating that FOXO-family transcription factors are essential throughout the reproductive axis, not only in the uterus.

The Evidence

The locus around rs7986407 has been identified in multiple large-scale GWAS efforts. The GWAS Catalog reports two fibroid associations at this variant: one with OR 1.07 (95% CI 1.04–1.10; p = 7 × 10⁻⁸; risk allele G) from studies in European-ancestry women, and a second association in a larger meta-analysis (p = 2 × 10⁻¹³; beta 0.064) where the A allele direction diverges — reflecting the complexities of phenotypic stratification across studies. A third entry in the GWAS Catalog records an association with uterine leiomyoma specifically (OR 0.93 per A allele; p = 2 × 10⁻¹⁸), consistent with a protective role of the A allele on fibroid risk.

The same A allele is associated with later age at natural menopause⁵⁵ later age at natural menopause
later menopause means longer total estrogen exposure across the reproductive lifespan at genome-wide significance (p = 4 × 10⁻¹⁹), suggesting that the A allele promotes prolonged functional ovarian activity. The relationship between these two A-allele phenotypes (later menopause and reduced fibroid risk, or context-dependent fibroid association) likely reflects the complex role of estrogen timing in uterine tissue biology.

A case-control study of 737 UF patients and 451 controls⁶⁶ case-control study of 737 UF patients and 451 controls
Ponomareva et al. 2024 found rs7986407 appearing in multiple gene-gene interaction models alongside rs547025 (SIRT3), rs2456181 (ZNF346), rs7907606 (STN1/SLK), and rs72709458 (TERT) — suggesting that the fibroid risk associated with this locus may be amplified or modified by co-occurring variants in related pathways. The SIRT3 connection is biologically plausible: sirtuin-family deacetylases directly regulate FOXO1 nuclear localization and activity, as shown by the SIRT1–FOXO1 axis in granulosa cells⁷⁷ SIRT1–FOXO1 axis in granulosa cells
miR-181a promotes SIRT1 downregulation, FOXO1 acetylation, and granulosa cell apoptosis via this axis.

Practical Actions

For women carrying two G alleles at rs7986407, the evidence may suggest a modest but biologically grounded susceptibility to uterine fibroid development, potentially acting through reduced FOXO1-mediated apoptotic surveillance in uterine smooth muscle cells. The fibroid phenotype in GG women may be modulated by factors that influence AKT pathway activity — including progestin exposure from hormonal contraception and body composition, as adipose tissue is a source of both estrogens and progestins.

Early pelvic ultrasound surveillance is the most actionable monitoring step for GG carriers. If fibroids are identified, awareness of the AKT/FOXO1 pathway biology may be relevant to treatment considerations, particularly given ongoing research into AKT-targeted fibroid therapies.

Interactions

The gene-gene interaction data from Ponomareva et al. 2024 and 2025 suggests that rs7986407 FOXO1 interacts with rs547025 SIRT3 in the context of uterine fibroid risk. SIRT3 (sirtuin 3) is a mitochondrial deacetylase with known roles in oxidative stress resistance and cellular longevity signaling. In the 2024 study, rs547025 SIRT3 showed the strongest individual protective effect against fibroids (C allele OR 0.61), while rs7986407 FOXO1 appeared repeatedly across interaction models. The biological rationale is compelling: SIRT3-family deacetylases regulate FOXO-family transcription factor activity through deacetylation, and FOXO1 acetylation status determines whether it can enter the nucleus to trigger apoptosis. A dual variant carrier — with both reduced SIRT3 protective capacity and a FOXO1 allele associated with fibroid risk — may face a convergent impairment of apoptotic regulation in uterine smooth muscle cells. Proposed compound action: SIRT3 rs547025 + FOXO1 rs7986407 — women carrying GG at rs7986407 (FOXO1, elevated fibroid risk) combined with TT at rs547025 (SIRT3, reduced protective effect) may have a compounded impairment of the SIRT3-FOXO1 apoptotic axis in uterine smooth muscle; recommended action would be earlier pelvic surveillance and monitoring of fibroid-related symptoms (heavy menstrual bleeding, pelvic pressure), plus consideration of lifestyle and dietary factors shown to support mitochondrial SIRT3 activity such as time-restricted eating and resistance exercise.

The endothelial protein C receptor (EPCR, encoded by the PROCR gene on chromosome 20) is a transmembrane glycoprotein on vascular endothelial cells that serves as the essential docking station for protein C activation¹¹ protein C activation
protein C is a vitamin K-dependent anticoagulant zymogen; when bound to EPCR, it is activated 20-fold more efficiently by the thrombin-thrombomodulin complex on the endothelial surface. Once activated, protein C (as APC — activated protein C) inactivates clotting factors Va and VIIIa, shutting down thrombin generation and protecting vessels from inappropriate clot formation. EPCR also anchors APC for cytoprotective PAR1 signaling²² cytoprotective PAR1 signaling
protease-activated receptor 1 (PAR1) triggers anti-inflammatory and endothelial barrier-stabilizing responses when activated by APC bound to EPCR — a distinct pathway from the pro-thrombotic PAR1 activation triggered by thrombin.

The rs867186 (S219G) variant substitutes glycine for serine at position 219 in the extracellular ectodomain³³ ectodomain
the portion of a transmembrane protein exposed on the cell surface, which can be proteolytically cleaved and released into circulation as a soluble fragment of EPCR. This single amino acid change dramatically alters how tightly EPCR is held at the cell surface — with consequences for both coagulation and inflammation.

The Mechanism

The Ser→Gly substitution at position 219 sits within the stalk region of EPCR adjacent to the transmembrane domain, exactly where ADAM metalloprotease-10 (ADAM10) cleaves EPCR⁴⁴ ADAM metalloprotease-10 (ADAM10) cleaves EPCR
ADAM proteases are zinc-dependent enzymes that shed ectodomains of membrane proteins; the 219Gly variant loosens the local protein structure, making the cleavage site more accessible to release soluble EPCR (sEPCR) into the bloodstream.

GG homozygotes have four-fold higher circulating sEPCR levels compared to AA homozygotes⁵⁵ GG homozygotes have four-fold higher circulating sEPCR levels compared to AA homozygotes
Ireland et al. Atherosclerosis 2005 — in vitro transfection confirmed increased basal release from cells expressing 219Gly. This has two opposing effects:

Pro-thrombotic pathway: sEPCR competitively sequesters circulating protein C away from the surface-bound EPCR that would activate it. Despite higher plasma protein C levels (because less is being activated and consumed), the functional anticoagulant response is blunted — protein C circulates but cannot dock efficiently on endothelial cells to be activated. Simultaneously, FVII and downstream coagulation activation markers (FIXpep, FXpep, prothrombin F1+2) rise proportionally with Gly allele dose⁶⁶ Gly allele dose
FVII elevated 6.9% in AG carriers and 23.4% in GG carriers vs AA, with a co-proportional rise in activated coagulation markers; Ireland et al. ATVB 2009, indicating net procoagulant shift despite the elevated protein C.

Anti-inflammatory pathway: sEPCR and APC-sEPCR complexes attenuate leukocyte-endothelial adhesion and vascular inflammation — explaining the paradoxical lower coronary artery disease risk in G allele carriers⁷⁷ paradoxical lower coronary artery disease risk in G allele carriers
Stacey et al., Nature Communications 2022 — PROCR-219Gly simultaneously reduces CAD risk through anti-inflammatory EPCR signaling while raising VTE risk through the coagulation FVII arm. This cross-phenotype pleiotropy — where the same variant decreases one vascular endpoint while increasing another — illustrates why simple "pro-thrombotic" labels can be misleading.

The Evidence

The VTE risk from rs867186 is among the most replicated associations in venous thrombosis genetics.

A HuGE meta-analysis of 37,415 cases and 84,406 non-cases across 25 studies⁸⁸ HuGE meta-analysis of 37,415 cases and 84,406 non-cases across 25 studies
Dennis et al. Blood 2012 — random-effects model, additive genetic model found each additional G allele increases VTE odds by 22% (OR 1.22, 95% CI 1.11–1.33, P < 0.001). No association was found with arterial MI.

A prospective Swedish cohort of 28,794 subjects followed through 2018⁹⁹ prospective Swedish cohort of 28,794 subjects followed through 2018
Manderstedt et al. Thrombosis and Haemostasis 2022 — Malmö Diet and Cancer Study, exome sequencing found only GG homozygosity — not AG heterozygosity — reached significance, with an adjusted HR of 1.5 (95% CI 1.1–2.0). This recessive-at-the-clinical-threshold pattern aligns with the dose-response in coagulation markers.

A subsequent meta-analysis of 5,768 cases and 30,017 controls¹⁰¹⁰ meta-analysis of 5,768 cases and 30,017 controls
Pituk et al. Front Cardiovasc Med 2023 — pooled analysis including their own Hungarian case-control study quantified genotype-specific risk more precisely: dominant model OR 1.27 (95% CI 1.11–1.46), recessive model OR 1.60 (95% CI 1.26–2.04), and GG versus AA OR 1.64 (95% CI 1.28–2.09). The same study found a non-significant trend toward higher VTE recurrence risk (OR 1.72, 95% CI 0.95–3.13, p = 0.075) in G carriers — a signal that may be meaningful for anticoagulation duration decisions.

At the genome-wide level, Thibord et al. Circulation 2022¹¹¹¹ Thibord et al. Circulation 2022
cross-ancestry GWAS of up to 81,669 VTE cases from 30 studies in European, African, and Hispanic populations — confirmed PROCR as an independent VTE locus among 135 significant signals and the Ghouse et al. Nature Genetics 2023¹²¹² Ghouse et al. Nature Genetics 2023
genome-wide meta-analysis of 81,190 cases and 1,419,671 controls — 93 risk loci, with PROCR among replication-confirmed signals both confirmed PROCR as an independent VTE risk locus in the largest genetic studies of venous thromboembolism conducted to date.

Practical Actions

For AG heterozygotes (the most common risk genotype at ~17.5% prevalence), the absolute risk increase is modest and typically does not alter standard clinical management. The key implication is awareness: recognizing an elevated baseline risk enables informed decisions around high-risk exposures such as prolonged immobility, surgery, or estrogen-containing contraceptives.

For GG homozygotes (~1% prevalence), the risk increment is clinically more meaningful (HR ~1.5 for incident VTE, OR ~1.64 in meta-analysis). This genotype warrants factoring into thrombotic risk stratification, particularly after a first unprovoked VTE when deciding on anticoagulation duration. PROCR S219G does not carry standalone indication for prophylactic anticoagulation, but it strengthens the case for extended therapy in ambiguous clinical scenarios.

The anti-inflammatory pleiotropic effect (lower CAD risk) does not require intervention — it is a passive benefit of the shedding mechanism.

Interactions

Factor V Leiden (rs6025) and prothrombin G20210A (rs1799963) are the strongest known inherited thrombophilia variants. Combining rs867186 with either of these creates a substantially higher cumulative VTE risk than any single variant alone, as these operate through independent mechanisms — FVII/PROCR pathway versus thrombin generation and fibrin deposition. Any carrier of rs867186 GG who also carries factor V Leiden or prothrombin mutation should be evaluated by a hematologist for thrombophilia risk stratification.

A second functional PROCR variant, Arg113Cys (rs146420040), was identified in the same Malmö cohort study and confers independent VTE risk (HR 1.3). The combination of both PROCR variants in the same individual has not been formally studied but would be expected to compound risk further.

IL-13¹¹ IL-13
Interleukin-13, a 12.5 kDa cytokine secreted primarily by activated Th2 CD4+ T cells, mast cells, and basophils is one of two master regulators of allergic disease — the other being IL-4. While IL-4 orchestrates the initial Th2 commitment and IgE class switching, IL-13 executes the downstream tissue effects: airway smooth muscle contraction, mucus hypersecretion by goblet cells, subepithelial fibrosis, and IgE amplification. Together they form the axis that makes allergic asthma, atopic eczema, and allergic rhinitis chronic rather than self-limiting.

The rs1800925 variant, also written as IL13 -1112C>T, sits in the IL13 gene promoter region on chromosome 5q31 — not in the protein-coding sequence, but upstream of it, in the DNA elements that control when and how much IL-13 gets made. The C allele is the reference and common form. The T allele, carried by about 20% of Europeans and 38% of Africans, silently rewires a key regulatory node in Th2 immune cells.

The Mechanism

The -1112 region of the IL13 promoter normally contains a STAT6 binding motif²² STAT6 binding motif
Signal transducer and activator of transcription 6 — the transcription factor activated downstream of IL-4 and IL-13 receptor signaling, which feeds back to suppress further IL-13 transcription. When STAT6 binds this site in Th2 cells, it partially represses IL13 gene expression, creating a negative feedback brake.

The T allele change at position -1112 disrupts the STAT6 binding motif and simultaneously creates a Yin-Yang 1 (YY1)³³ Yin-Yang 1 (YY1)
A zinc-finger transcription factor with context-dependent activating or repressing functions, named for its ability to act as both activator and repressor depending on cofactors present binding site that overlaps the STAT6 motif. YY1 then competes with STAT6 for binding to this locus. In polarized Th2 cells — exactly the context of active allergic disease — this competition tips in favor of YY1, attenuating STAT6-mediated repression and selectively boosting IL13 transcription⁴⁴ attenuating STAT6-mediated repression and selectively boosting IL13 transcription. The effect is Th2-selective: the same variant has opposing effects in non-polarized T cells, where the nuclear milieu favors STAT6 binding.

The consequence is increased IL-13 production at the tissue level in allergic individuals, which drives goblet cell hyperplasia and mucus secretion in airways, enhances IgE production by B cells (via IL-4Rα/IL-13Rα1 type II receptor), reduces airway responsiveness by altering smooth muscle physiology, and promotes subepithelial fibrosis in chronic disease. Individuals homozygous for the T allele produce measurably more IL-13 from activated Th2 cells.

The Evidence

The -1112C>T functional mechanism was established in 2006 by Cameron et al., who used ChIP assays and EMSA in primary human Th2 cells to show allele-specific STAT6 and YY1 binding at the -1112 locus and confirmed increased IL-13 secretion in TT homozygous subjects⁵⁵ Cameron et al., who used ChIP assays and EMSA in primary human Th2 cells to show allele-specific STAT6 and YY1 binding at the -1112 locus and confirmed increased IL-13 secretion in TT homozygous subjects. This remains the definitive mechanistic study.

Clinical associations span asthma, COPD, and atopic disease. A 2023 meta-analysis (Gaceja et al.) of 11 studies including 2,895 asthma cases and 2,914 controls⁶⁶ 2023 meta-analysis (Gaceja et al.) of 11 studies including 2,895 asthma cases and 2,914 controls found the TT genotype significantly associated with allergic asthma risk in Asian populations under the recessive model (OR 1.48, 95% CI 1.14–1.93) and codominant model (TT vs CC: OR 1.66, 95% CI 1.27–2.17). West Asian populations (Iranian and Saudi) showed the strongest effect (OR 2.17).

For lung disease, a 2017 meta-analysis of 9 studies (Liao et al., 3,077 participants) found the T allele associated with COPD risk overall⁷⁷ 2017 meta-analysis of 9 studies (Liao et al., 3,077 participants) found the T allele associated with COPD risk overall with OR 1.57 (95% CI 1.21–2.04), driven by both Asian (OR 1.88) and Caucasian (OR 1.30) subgroups.

A particularly important pharmacogenomic finding emerged from the CAMP childhood asthma study: Hunninghake et al. (2007) found that the T allele was associated with increased asthma exacerbations specifically in children on inhaled corticosteroids⁸⁸ Hunninghake et al. (2007) found that the T allele was associated with increased asthma exacerbations specifically in children on inhaled corticosteroids (P=0.02) — the first report of a potential negative gene-ICS interaction for this locus. This suggests T carriers may have attenuated corticosteroid benefit from standard inhaled therapy.

The variant also interacts with environmental exposures. Choudhry et al. (2008) demonstrated that IL13 rs1800925 genotype modifies the effect of prenatal tobacco smoke exposure on persistent wheeze in childhood⁹⁹ Choudhry et al. (2008) demonstrated that IL13 rs1800925 genotype modifies the effect of prenatal tobacco smoke exposure on persistent wheeze in childhood, and the NSHD cohort found evidence for smoking-rs1800925 interaction on allergy risk across the life course¹⁰¹⁰ evidence for smoking-rs1800925 interaction on allergy risk across the life course. T carriers who smoke face compounded risk beyond either factor alone.

Practical Actions

For T allele carriers — particularly those with existing atopic disease — the key intervention targets are the IL-4/IL-13 Th2 axis and mucus pathway, alongside monitoring of corticosteroid effectiveness. Since IL-13 itself is now a validated biologic drug target (tralokinumab, lebrikizumab), the biology underlying this SNP is clinically actionable at the therapeutic level.

Total and specific IgE measurement quantifies the downstream consequence of enhanced IL-13 signaling and helps identify the specific allergens being amplified by your Th2 bias. Monitoring IgE trends over time provides objective feedback on whether dietary, supplement, or medication interventions are effective.

For CT carriers with asthma managed on inhaled corticosteroids, the possible ICS-rs1800925 interaction warrants attention to whether current treatment is achieving expected control. If asthma remains poorly controlled despite standard ICS therapy, discussing add-on therapies (LABA, leukotriene modifiers, or biologic options) with a specialist is appropriate.

Interactions

The most important interaction partner is [rs20541 | IL13 R130Q coding variant — the Q130 minor allele (A) directly increases IL-13 protein activity], which is in moderate LD with rs1800925. The -1112T allele increases the amount of IL-13 made; the Q130/rs20541-A allele increases the activity of the protein made. Carrying risk alleles at both loci compounds IL-13 pathway amplification through independent mechanisms — the TA haplotype (rs1800925-T + rs20541-A) is consistently the highest-risk haplotype for atopic disease.

The [rs1801275 | IL4R Q576R — gain-of-function variant in the shared IL-4/IL-13 receptor alpha chain] from the same Th2 pathway amplifies signaling from both IL-4 and IL-13. A carrier of rs1800925-T (more IL-13 produced) with rs1801275-G (more IL-13 signal transduced) faces dual amplification of the same pathway.

Smoking exposure warrants particular attention: multiple studies show that tobacco smoke interacts with rs1800925 genotype to amplify wheeze and allergy risk beyond what either factor alone predicts, likely because smoke-induced airway inflammation further activates Th2 cells that are already primed to over-produce IL-13.

N-acetyltransferase 2 (NAT2) is a Phase II ¹¹ Phase II detoxification conjugates reactive intermediates from Phase I with small molecules to make them water-soluble and excretable detoxification enzyme that adds an acetyl group to aromatic amines and hydrazines, making them water-soluble so your body can excrete them. These substrates include environmental carcinogens from cigarette smoke, heterocyclic amines ²² Heterocyclic amines are carcinogenic compounds formed when meat is cooked at high temperatures, especially charring or grilling from cooked meat, and medications like isoniazid (tuberculosis treatment) and sulfasalazine.

The Mechanism

The I114T variant (rs1801280) changes isoleucine to threonine at position 114 of the NAT2 protein. The C allele (Thr) destabilizes the enzyme, leading to faster degradation and lower acetylation capacity. This is one of the most common "slow acetylator" alleles in European populations, characterizing the NAT2*5B haplotype. The C allele frequency is remarkably high in Europeans (~44%) but very rare in East Asians (~3%).

Slow vs. Rapid Acetylators

NAT2 acetylator status is determined by the combination of multiple variants (rs1801280, rs1799930, rs1208). You need two slow alleles (one from each parent) to be a slow acetylator. About 50-60% of Europeans are slow acetylators ³³ This high frequency suggests slow acetylation may have been advantageous in certain ancestral environments due to the high frequency of these variants, compared to only 10-20% of East Asians.

Clinical Significance

Slow acetylators have increased risk of bladder cancer from occupational exposure to aromatic amines. A major meta-analysis⁴⁴ major meta-analysis
Garcia-Closas M et al. NAT2 slow acetylation and bladder cancer risk. Lancet, 2005 found an overall OR of 1.4 (95% CI 1.2-1.7) for bladder cancer in slow acetylators, with stronger effects in cigarette smokers. Slow acetylators also require dose adjustments for isoniazid and are more prone to drug-induced lupus from certain medications. However, slow acetylation may actually be protective in some contexts - rapid acetylators have higher colorectal cancer risk from heterocyclic amines in well-done meat.

Practical Advice

If you are a slow acetylator: minimize exposure to cigarette smoke (active and secondhand), moderate consumption of heavily charred or grilled meats, and inform your doctor of your acetylator status if prescribed isoniazid or other NAT2 substrate medications.

The TMPRSS3 gene encodes a type II transmembrane serine protease¹¹ type II transmembrane serine protease
Anchored to the cell membrane with its catalytic serine protease domain facing the extracellular space; expressed in cochlear inner and outer hair cells, spiral ganglion neurons, and the stria vascularis essential for the survival of cochlear hair cells at the onset of hearing. Of the more than 87 documented TMPRSS3 pathogenic variants, the p.Ala306Thr missense change caused by c.916G>A is the single most common allele detected across all populations²² the p.Ala306Thr missense change caused by c.916G>A is the single most common allele detected across all populations
Identified in Korean, Chinese, Dutch, and German families; classified as a Korean and Chinese founder mutation; the most frequently reported mutation in published TMPRSS3 literature — making it a high-priority target for both clinical recognition and emerging gene therapy approaches.

This variant is catalogued in ClinVar (variation 46131) as Pathogenic/Likely pathogenic for autosomal recessive nonsyndromic hearing loss 8 (DFNB8), with 17 submitting laboratories providing criteria-based evidence, and no conflicting classifications.

The Mechanism

TMPRSS3 is synthesized as an inactive single-chain precursor (zymogen) that must undergo autocatalytic self-cleavage³³ autocatalytic self-cleavage
The serine protease domain cleaves itself at a specific arginine residue to release the active two-chain form; TMPRSS3 is one of the few serine proteases that activates itself rather than relying on an upstream activator to become active. This active form then contributes to epithelial sodium channel (ENaC) activation in cochlear hair cells and, through as-yet incompletely characterized pathways, supports hair cell survival.

The p.Ala306Thr substitution places a threonine — a bulkier, polar amino acid — at position 306 within the serine protease catalytic domain⁴⁴ serine protease catalytic domain
The catalytic triad of serine proteases (His, Asp, Ser) requires precise spatial arrangement for activity; Ala306 sits adjacent to the active-site residue Asp304, and any perturbation of local geometry can disrupt substrate binding and catalysis. Molecular modeling shows that wild-type Ala306 forms two salt bridges with Thr254, while mutant Thr306 forms an additional unnatural salt bridge with Val291 — a structural perturbation predicted to directly impair catalytic function. Crucially, p.Ala306Thr does not abolish TMPRSS3 autocatalytic processing the way the R216L null allele does; instead it reduces activity, making it a hypomorphic variant⁵⁵ hypomorphic variant
A hypomorph retains partial protein function, as opposed to an amorph (null). TMPRSS3 A306T knockin mice develop delayed-onset progressive hearing loss rather than the complete congenital deafness seen with biallelic null alleles, confirming residual function. The residual activity is insufficient for long-term cochlear hair cell survival but supports initial postnatal hearing — explaining the postlingual, progressive clinical phenotype.

The Evidence

Founder mutation status is established for multiple populations. In the Chinese population⁶⁶ In the Chinese population
Zheng et al. 2017, screening 151 ARNSHL families lacking GJB2/SLC26A4 mutations; TMPRSS3 accounted for 4.6% of cases; c.916G>A was found in 2% of all alleles; haplotype analysis showed linkage disequilibrium across 4/6 families supporting a common ancestor, this allele is clearly a founder mutation. In Korea⁷⁷ In Korea
Carrier rate among Korean postlingual hearing loss patients with TMPRSS3 mutations was 8.3%; p.A306T is the dominant founder allele with haplotype evidence, the same conclusion holds. It has also been independently found in Dutch and German families.

Genotype-phenotype correlations reveal a pattern with clear clinical relevance. Weegerink et al. 2011 in Dutch DFNB8/10 families⁸⁸ Weegerink et al. 2011 in Dutch DFNB8/10 families
8 families studied; the study established the principle that TMPRSS3 allele combinations predict phenotype: two severe alleles → DFNB10 (prelingual profound), one severe + one mild → DFNB8 (postlingual progressive) established p.Ala306Thr as a severe allele. When p.Ala306Thr pairs with a truncating or null allele (such as rs727503493 c.208delC frameshift or rs137853000 R216L), the result is typically prelingual profound hearing loss (DFNB10 phenotype). When it pairs with a mild missense allele, postlingual progressive loss (DFNB8 phenotype) results. This distinction has major clinical implications: DFNB8 patients retain speech for years to decades, while DFNB10 patients require intervention from infancy.

The A306T mouse model provides mechanistic confirmation. Du et al. 2023⁹⁹ Du et al. 2023
Molecular Therapy; CRISPR-Cas9 knockin of the human c.916G>A allele into CBA/CaJ mice created Tmprss3A306T/A306T homozygous animals that develop late-onset progressive HL beginning after 10.5 months, with average threshold elevation of ~26 dB by 22.5 months — exactly recapitulating the human DFNB8 pattern created and validated an A306T knockin mouse model. A single AAV2-hTMPRSS3 injection into 18.5-month-old mice (equivalent to a middle-aged adult human) restored hearing thresholds to wild-type levels, preserved outer hair cell survival, and tripled spiral ganglion neuron survival — making this the first successful gene therapy demonstration in an aged mouse model of hereditary deafness.

Cochlear implant outcomes are favorable. Colbert et al. 2024¹⁰¹⁰ Colbert et al. 2024
127 patients, 16 centers, 6 countries; mean word recognition score 76%; age at implantation is the dominant outcome predictor — each year of delay associated with measurable speech perception decrement confirmed excellent outcomes across the TMPRSS3 patient population. Individual published cases of A306T compound heterozygotes have achieved 65–91% phoneme scores with cochlear implants.

Practical Implications

For confirmed biallelic A306T carriers (TT), or compound heterozygotes carrying one A306T allele and one other pathogenic TMPRSS3 allele, the clinical priority is early audiological characterization, progressive monitoring, and timely cochlear implant referral. The progressive nature of DFNB8 means that TMPRSS3-related hearing loss often presents in childhood with high-frequency loss that progresses over years to decades — a pattern that may be initially confused with noise-induced or idiopathic progressive loss. Genetic diagnosis changes the trajectory by enabling intervention planning.

Looking forward, the AAV-TMPRSS3 gene therapy approach validated in the A306T mouse model represents a genuine therapeutic pipeline specifically targeted to this allele. Carriers with this mutation should be tracked in TMPRSS3 natural history registries that will feed into gene therapy trials.

Interactions

The dominant interaction is compound heterozygosity with other TMPRSS3 pathogenic alleles. Because p.Ala306Thr is a severe (not null) allele:

• A306T + null allele (rs137853000 R216L, rs727503493 c.208delC): Expected DFNB10 — prelingual profound deafness. The null allele contributes no function; A306T's residual activity is insufficient to rescue the phenotype to postlingual onset.
• A306T + mild missense (p.Ala426Thr, p.Ala138Glu, p.Thr248Met, or intronic variants): Expected DFNB8 — postlingual progressive hearing loss, typically onset in childhood to early adulthood, ski-slope audiogram.
• Homozygous A306T/A306T: Also causes DFNB8-type progressive HL; the mouse model Tmprss3A306T/A306T confirms delayed-onset progressive loss, not congenital profound deafness.

The severity-based prediction framework is clinically actionable: when a TMPRSS3 evaluation returns A306T on one allele, comprehensive sequencing of the second allele determines whether the patient faces DFNB8 (mild + mild = postlingual) or DFNB10 (mild + severe = prelingual profound) outcome. See also rs137853000 (R216L, complete null allele) and rs727503493 (c.208delC frameshift) for the other shipped TMPRSS3 pathogenic alleles.

A possible digenic interaction with GJB2 (connexin 26)¹¹¹¹ GJB2 (connexin 26)
GJB2 encodes the gap junction protein connexin 26, the most common cause of genetic hearing loss in most populations; initial reports suggested TMPRSS3/GJB2 digenic cases, but larger series have not confirmed this as a distinct entity has been explored but is not established. When a single TMPRSS3 pathogenic allele is found in a hearing-loss patient, comprehensive deafness gene panel testing including GJB2 should be performed before concluding the patient is a carrier rather than a compound heterozygote.

CYP3A4 is the most versatile drug-metabolizing enzyme in the human body, responsible for processing approximately 50% of all prescription medications — from transplant immunosuppressants and statins to psychiatric drugs and opioids. The *1G variant (rs2242480) sits in intron 10 of CYP3A4, a seemingly innocuous location. Yet its effects on enzyme expression are clinically meaningful enough to appear on transplant pharmacogenomics panels and to influence tacrolimus and sirolimus trough concentrations by two- to three-fold in transplant patients.

Unlike the well-characterized *22 splice variant (rs35599367), *1G does not disrupt a splicing factor binding site. Instead, its mechanism runs through an indirect regulatory pathway involving a long noncoding RNA.

The Mechanism

Collins and Wang (2022)¹¹ Collins and Wang (2022)
Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the CYP3A4*1G association identified AC069294.1, an antisense [long noncoding RNA | lncRNA: a class of RNA molecules longer than 200 nucleotides that do not code for protein but regulate gene expression] as a negative regulator of both CYP3A4 and CYP3A5. Knockdown of this lncRNA increased CYP3A4 mRNA approximately 3-fold; overexpression reduced it by 89%. The rs2242480 T allele (*1G) sits approximately 2.7 kb upstream of the lncRNA gene and is associated with 1.26-fold increased lncRNA expression (P<0.0001). Downstream of this, *1G carriers show 31% lower CYP3A4 expression (P=0.008) and 39% lower CYP3A5 expression (P=0.004). Yang et al. (2023)²² Yang et al. (2023)
CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells confirmed this in engineered cell lines, showing allele-dependent reduction in both mRNA and protein, with decreased tacrolimus metabolism particularly in heterozygous GA (plus-strand: CT) cells.

On the chromosome, CYP3A4 lies on the minus strand. The variant is described in coding-strand notation as c.1026+12G>A, but in genome files (which always use the plus strand), it reads as a C>T change at chromosome 7 position 99,763,842 (GRCh38). The reference allele C corresponds to the wild-type *1 haplotype; the alternate T allele defines *1G.

The Evidence

The most clinically relevant evidence comes from transplant medicine. Miura et al. (2011)³³ Miura et al. (2011)
Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients followed 136 renal transplant recipients and found that CYP3A4*1G carriers had significantly lower dose-adjusted tacrolimus AUC and trough concentrations — an effect approximately half the magnitude of CYP3A5 expresser status but independently significant (P=0.018). Dong et al. (2022)⁴⁴ Dong et al. (2022)
CYP3A7, CYP3A4, and CYP3A5 polymorphisms in recipients influence tacrolimus concentrations after liver transplantation found CC recipients had approximately twice the dose-adjusted trough concentration as TC/TT carriers (189.8 vs 99.7 ng/mL per mg/kg/day, P<0.001) in 138 liver transplant patients. Uesugi et al. (2013)⁵⁵ Uesugi et al. (2013)
CYP3A4*1G polymorphism and tacrolimus in liver transplant patients observed similar direction effects in a 410-patient Japanese cohort, with CYP3A4*1/*1 donors yielding 37% higher concentration/dose ratios than *1/*1G donors in the first week post-transplant.

For sirolimus, a 2020 study of 69 renal transplant recipients⁶⁶ a 2020 study of 69 renal transplant recipients
CYP3A4 rs2242480 associated with sirolimus trough concentrations found CC carriers achieved 533 vs 157–143 (ng/mL)/mg/kg trough concentrations compared to TC and TT carriers respectively (P<0.0001) — a greater than three-fold difference that could mean the difference between subtherapeutic and supratherapeutic exposure.

Beyond transplant medicine, a meta-analysis of 18 studies encompassing 2,546 epilepsy patients⁷⁷ a meta-analysis of 18 studies encompassing 2,546 epilepsy patients
Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism found the *1G allele (G in coding-strand notation, T in plus-strand) markedly reduced plasma carbamazepine concentrations. For psychiatric drugs, Dai et al. (2026)⁸⁸ Dai et al. (2026)
CYP3A4 rs2242480 and lurasidone in Chinese bipolar depression modeled 133 patients and found CC carriers had 25% lower lurasidone clearance than TT carriers (330 vs 441 L/h), translating to meaningfully higher drug exposure at equivalent doses.

Practical Actions

The primary clinical application of CYP3A4*1G genotyping is in transplant medicine, where tacrolimus and sirolimus have narrow therapeutic windows — the difference between rejection and toxicity. CC homozygotes (the wild-type) metabolize CYP3A4 substrates efficiently and require standard doses. CT heterozygotes (*1/*1G) have moderately reduced enzyme activity; for tacrolimus and sirolimus, starting doses may need upward adjustment or more frequent monitoring to reach target trough levels. TT homozygotes (*1G/*1G) have the greatest reduction in CYP3A4 expression and the lowest drug clearance; they may achieve target tacrolimus/sirolimus levels at lower doses than standard, reducing nephrotoxicity risk.

For CYP3A4-metabolized statins (atorvastatin, simvastatin, lovastatin), TT carriers accumulate higher statin levels and may be at increased risk of myopathy at standard doses. The statin evidence is more limited than for immunosuppressants, but the directionality is consistent.

Interactions

CYP3A4*1G and CYP3A4*22 (rs35599367) are independent variants in the same gene. A patient carrying both the *1G and *22 alleles would be expected to have compounded reductions in CYP3A4 activity. Similarly, CYP3A5 expresser status (rs776746 *1/*3) strongly modifies the *1G effect — Miura et al.⁹⁹ Miura et al.
Tacrolimus PKs in renal transplant showed the lowest dose-adjusted AUC occurred in patients who were both *1G carriers and CYP3A5 expressers, because CYP3A5 expression itself boosts metabolic capacity that the *1G variant then partially suppresses. For a complete picture of CYP3A metabolizer phenotype, both rs2242480 (*1G) and rs776746 (CYP3A5*3) should be considered together.

Every time you eat, your small intestine releases a hormone called GIP (glucose-dependent insulinotropic polypeptide)¹¹ GIP (glucose-dependent insulinotropic polypeptide)
Also called gastric inhibitory polypeptide. One of two major incretin hormones that amplify insulin release after a meal and suppress appetite via the gut-brain axis. GIP works alongside GLP-1 to drive up to 70% of the insulin your pancreas secretes after eating — a system called the incretin effect. The rs2291725 variant in the GIP gene changes a single amino acid at position 103 of the precursor protein (Serine → Glycine), altering the bioactivity of the mature hormone.

This variant is unusual in human genetics: the Glycine form (C allele on the plus strand) appears to have undergone positive selection²² positive selection
Evolutionary selection where a beneficial variant spreads faster through a population than neutral drift would explain in Eurasian populations roughly 8,100 years ago — approximately when agriculture was expanding across Eurasia. The derived allele now reaches 71.8% in East Asian populations and 52.7% in Europeans, while remaining rare in African populations (11.6%), where the ancestral Serine form predominates at 88.4%.

The Mechanism

The Ser→Gly substitution at GIP amino acid 55 (position 103 in the prepropeptide) alters the biochemical behavior of the mature hormone in two ways, as shown by Chang et al. 2011³³ Chang et al. 2011
Chang CL et al. Adaptive selection of an incretin gene in Eurasian populations. Genome Research, 2011:

First, the Gly variant (C allele, GIP55G) generates significantly higher cAMP⁴⁴ cAMP
Cyclic AMP — the intracellular second messenger that GIP triggers in pancreatic beta cells and adipocytes to drive insulin secretion production in GIPR-expressing cells compared to the ancestral Ser form (GIP55S), with a statistically significant difference (p < 0.01). This means stronger receptor activation per molecule of hormone released.

Second, the Gly variant is more resistant to serum degradation, giving the hormone a longer effective half-life in circulation. The ancestral Ser form is cleaved more readily by dipeptidyl peptidase-4 (DPP-4)⁵⁵ dipeptidyl peptidase-4 (DPP-4)
The enzyme that rapidly inactivates both GIP and GLP-1 by removing their first two amino acids; DPP-4 inhibitors (gliptins) work by blocking this degradation, shortening its active window. Together, higher intrinsic potency and greater stability mean carriers of the Gly allele experience more powerful postprandial incretin signaling per meal.

GIP receptors are expressed not only in the pancreas and adipose tissue but also in the hypothalamus, hippocampus, and brainstem — areas that regulate appetite, reward, and the sleep-wake interface. This gut-brain axis expression explains why GIP variation appears in large-scale GWAS of sleep phenotypes alongside its better-characterized metabolic roles.

Importantly, GIP is one of two targets of tirzepatide (Mounjaro / Zepbound), the dual GIP/GLP-1 receptor agonist. Genetic variation in GIP and GIPR (the receptor gene) is increasingly recognized as relevant to treatment response prediction for this drug class.

The Evidence

Chang et al. (2011)⁶⁶ Chang et al. (2011)
Chang CL et al. Adaptive selection of an incretin gene in Eurasian populations. Genome Research, 2011 analyzed 944 individuals across global populations from the HGDP-CEPH cohort and identified clear signatures of positive selection for the derived C allele in Eurasian — particularly East Asian — populations. The empirical selection p-values ranged from 0.004 to 0.058 across population comparisons. In functional assays, GIP55G showed higher cAMP production (p < 0.01) and greater serum stability (p = 0.002) than GIP55S, suggesting that enhanced incretin response to dietary carbohydrate may have conferred survival advantage in agricultural societies.

A cardiovascular risk study in 666 Chinese type 2 diabetic patients by Ma et al. (2018)⁷⁷ Ma et al. (2018)
Ma X et al. Genetic variability of the GIP gene is involved in premature coronary artery disease in Chinese patients with T2D. J Diabetes Res, 2018 found that, in individuals with premature CAD (men <55, women <65), carriers of the C allele had higher CAD risk than non-carriers (OR 1.627, p = 0.015), while T/T or T/C genotypes (with at least one ancestral T allele) were associated with lower CAD risk (adjusted OR 0.769, p = 0.013). This paradoxical finding — the higher-bioactivity allele conferring CAD risk in the context of established diabetes — suggests the relationship between GIP activity and cardiovascular outcomes is mediated by metabolic context rather than being a simple dose-response.

The Lane et al. (2019) insomnia GWAS⁸⁸ Lane et al. (2019) insomnia GWAS
Lane JM et al. Biological and clinical insights from genetics of insomnia symptoms. Nature Genetics, 2019 conducted in 453,379 UK Biobank participants identified 57 genome-wide significant loci for insomnia symptoms, with mapped biological pathways enriched for gut-brain signaling and metabolic hormone networks. The GIP locus on chromosome 17q21 sits within a region showing pleiotropic associations across metabolic, sleep, and cardiovascular traits.

A large coronary artery disease GWAS by the CARDIoGRAMplusC4D Consortium (2011)⁹⁹ by the CARDIoGRAMplusC4D Consortium (2011)
Schunkert H et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011 confirmed the 17q21 locus — which encompasses GIP — as genome-wide significant for CAD (n > 22,000 cases).

Practical Actions

The key modifiable variable in GIP biology is meal timing and composition. GIP is secreted within minutes of eating fat and carbohydrate — its release is driven by nutrient contact with K-cells in the proximal small intestine. For carriers of the lower-bioactivity Ser allele (T/T), optimizing meal timing relative to sleep may help compensate for the weaker postprandial incretin signal. Finishing eating at least 3–4 hours before bed reduces the nocturnal GIP stimulation that can fragment sleep architecture in individuals with altered gut-brain hormonal signaling.

GIP also directly promotes fat storage in adipocytes (it upregulates LPL activity and promotes triglyceride uptake), so carriers of two copies of the T allele — with lower GIP bioactivity — may have different fat partitioning responses to high-fat vs high-carbohydrate diets than Gly/Gly carriers.

For users taking or considering tirzepatide (which agonizes both the GIP and GLP-1 receptors), variants in the GIP gene pathway are increasingly being studied as potential response modifiers. The ancestral Ser form (T allele) may be associated with lower endogenous GIPR activation, potentially altering the pharmacological response landscape.

Interactions

GIP works in concert with GLP-1 (encoded by GCG on chromosome 2) and the GIP receptor (GIPR, chromosome 19). GIPR variants — particularly rs1800437 (E354Q) — modify receptor sensitivity and are separately catalogued. The combined effect of GIP Ser103Gly (rs2291725) and GIPR variants on incretin potency and sleep quality is a plausible compound interaction: individuals with both a lower-bioactivity GIP ligand (T/T) and a reduced-sensitivity GIP receptor may have the most attenuated gut-brain incretin signaling.

The GIP locus at 17q21 lies near genes involved in coronary artery disease (UBE2Z, ATP5G1, SNF8). Functional interaction with rs46522 (UBE2Z-GIP locus) in the context of T2D risk has been reported, though this reflects LD structure rather than direct gene-gene interaction.

Apolipoprotein C-III (apoCIII) is the body's master brake on triglyceride clearance. It coats triglyceride-rich VLDL particles and inhibits the lipoprotein lipase¹¹ lipoprotein lipase
The enzyme that breaks down triglycerides in blood, releasing fatty acids for tissues that would otherwise clear them. After a meal, healthy physiology suppresses apoCIII secretion — letting triglycerides clear quickly. The rs2854117 variant disrupts that suppression, keeping apoCIII elevated and triglycerides circulating longer.

The Mechanism

The APOC3 gene sits on chromosome 11 in a cluster with APOA1, APOA4, and APOA5. Its promoter contains a negative insulin response element (nIRE)²² negative insulin response element (nIRE)
A DNA sequence where insulin binding normally represses gene transcription that ordinarily drives down APOC3 output after eating. The C-482T variant (T allele at rs2854117) lies within this nIRE, altering its sequence and blunting the insulin signal that should silence APOC3. The result is persistently elevated apoCIII protein, which keeps VLDL particles circulating and slows triglyceride clearance from the bloodstream.

The -482 position is in strong linkage disequilibrium with rs2854116 (T-455C), and the two variants are usually studied together as part of an APOC3 promoter haplotype. Both sit within the same nIRE, and their combined effect on insulin-mediated suppression appears additive.

The Evidence

A 2003 prospective cohort study in 502 adults³³ 2003 prospective cohort study in 502 adults
Waterworth et al. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003 found that T allele homozygotes had a 33% lower 30-minute insulin increment after glucose challenge, and approximately 10% higher non-esterified fatty acid (NEFA) levels, compared to CC homozygotes. Both variants (at -482 and -455) also interacted with smoking to worsen fasting triglycerides.

A 2001 epidemiological study in 983 French adults⁴⁴ 2001 epidemiological study in 983 French adults
Dallongeville et al. Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001 confirmed that the -482 T allele modifies the relationship between plasma insulin and triglyceride-rich LpCIII:B particles, particularly in women.

The most direct disease-risk evidence comes from a 2025 Chinese case-control study in 440 participants⁵⁵ 2025 Chinese case-control study in 440 participants
Ye et al. Associations between APOC3 and ANGPTL8 gene polymorphisms with MASLD risk. 2025, which found that CT+TT carriers had 1.9-fold higher odds of metabolic dysfunction-associated steatotic liver disease (MASLD) compared with CC carriers (OR 1.9, 95% CI 1.2–3.2), with triglycerides mediating 62.6% of that genetic effect.

Pharmacogenomic data from the GOLDN trial⁶⁶ GOLDN trial
Liu et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate. Pharmacogenetics and Genomics, 2009 showed that the T minor allele is associated with a blunted triglyceride-lowering response to fenofibrate (p=0.026), unlike other variants in the same cluster which enhance the response. This suggests the -482 variant alters the transcriptional pathway fenofibrate relies on.

Evidence is mixed on broader cardiovascular endpoints: a meta-analysis found no significant association with ischemic stroke⁷⁷ found no significant association with ischemic stroke
Zhang et al. The impact of APOA5, APOB, APOC3 and ABCA1 gene polymorphisms on ischemic stroke. Gene, 2017, and studies in European cohorts have not consistently shown a NAFLD/liver-fat association, suggesting ethnic and dietary context modulate the phenotypic expression.

Practical Actions

T allele carriers should focus on the two levers most directly linked to apoCIII activity: dietary fat quality and post-meal triglyceride clearance. Limiting refined carbohydrates and fructose is particularly relevant because both raise apoCIII transcription independently of the promoter variant. Long-chain omega-3 fatty acids (EPA and DHA) suppress apoCIII at the transcriptional level, partially compensating for the blunted insulin signal.

Fasting triglyceride testing is the most direct way to track phenotypic expression of this variant. Levels consistently above 150 mg/dL suggest the variant is having a meaningful effect and warrant dietary intervention. Fenofibrate may have a reduced effect in T carriers; if fibrate therapy is being considered, this variant is worth noting to the prescribing clinician.

Interactions

rs2854117 is in strong linkage disequilibrium with rs2854116 (T-455C, the other APOC3 promoter nIRE variant). Carriers of the T allele at rs2854117 are very likely to also carry the C allele at rs2854116. Studies generally show additive effects on apoCIII dysregulation when both promoter variants are co-inherited. The APOC3 3'-SstI variant (rs5128) operates through a different mechanism (post-transcriptional or 3'-regulatory) and has independent effects on VLDL — its effect can stack with the promoter haplotype.

The APOA5 rs662799 variant is a frequent companion in hypertriglyceridemia genetic panels and encodes a different step in the VLDL-triglyceride axis. When rs662799 risk allele co-occurs with the rs2854117 T allele, the combined triglyceride burden is likely additive, though published compound analyses are limited.

The WNT16 gene encodes a signaling protein¹¹ signaling protein
WNT16 is a member of the Wingless-related integration site (WNT) family of secreted glycoproteins that regulate bone homeostasis crucial for bone development and maintenance. Among all the WNT family members, WNT16 stands out for its specific and powerful effect on cortical bone — the dense outer layer of bone that provides structural strength and accounts for about 80% of the skeleton's mass. The rs3801387 variant lies in the last intron of WNT16 and is part of a regulatory region²² regulatory region
The variant is in high linkage disequilibrium with other functional variants including eQTLs that affect WNT16 and neighboring gene expression that influences how much WNT16 protein your bone cells produce.

The Mechanism

WNT16 is primarily expressed by osteoblasts³³ primarily expressed by osteoblasts
bone-forming cells lining the cortical bone surface, where it plays a dual role in maintaining bone strength. First, it acts directly on osteoclast precursors to inhibit their differentiation into bone-resorbing osteoclasts through a non-canonical signaling pathway. Second, it increases expression of osteoprotegerin (OPG) in osteoblasts, which acts as a decoy receptor for RANKL, further suppressing osteoclastogenesis. The net result is reduced bone resorption on the inner (endocortical) surface, preserving cortical thickness.

The rs3801387 variant affects this system through regulatory mechanisms. The A allele is associated with lower bone mineral density⁴⁴ A allele is associated with lower bone mineral density, while the G allele appears protective, correlating with higher BMD and thicker cortical bone. In a region of high linkage disequilibrium spanning WNT16 and the adjacent FAM3C gene, rs3801387 tags multiple functional variants that influence gene expression. This makes rs3801387 a reliable proxy for overall WNT16 function, which is why it has emerged as the sentinel SNP in multiple GWAS⁵⁵ sentinel SNP in multiple GWAS for bone traits.

The Evidence

Multiple large-scale studies have established rs3801387's role in bone health. A GWAS meta-analysis of cortical bone thickness in 5,878 individuals⁶⁶ GWAS meta-analysis of cortical bone thickness in 5,878 individuals identified WNT16 variants associated with both cortical thickness and forearm BMD at genome-wide significance (P = 6.2×10⁻⁹ for cortical thickness). The study also demonstrated association with forearm fracture risk (OR = 1.33 for fractures, P = 7.3×10⁻⁹). A meta-analysis restricted to premenopausal women (n=4,061)⁷⁷ meta-analysis restricted to premenopausal women (n=4,061) found rs3801387 reached genome-wide significance for lumbar spine BMD (P = 1.7×10⁻⁹ in discovery, improving to P = 1.3×10⁻¹¹ in joint analysis). Each copy of the minor G allele was associated with approximately 0.16 SD higher BMD, explaining 0.6-1.8% of BMD variance.

Functional validation came from Wnt16 knockout mice⁸⁸ Wnt16 knockout mice, which developed spontaneous fractures due to 27% thinner cortical bone and high cortical porosity. Bone strength was reduced by 43-61% at both femur and tibia. Critically, trabecular (spongy) bone was unaffected, confirming WNT16's cortical-specific role. The effect persists through the lifespan — conditional inactivation in adult mice⁹⁹ conditional inactivation in adult mice showed that WNT16 continues to regulate cortical thickness even after peak bone mass is achieved, suggesting interventions targeting this pathway could benefit older adults.

Interestingly, the effect of rs3801387 may interact with mechanical loading. A study of male endurance runners¹⁰¹⁰ male endurance runners found AA genotype runners had 14% lower lumbar spine BMD than AA genotype non-athletes (P < 0.001), while AG+GG genotype runners actually had 5% higher leg BMD than non-athletes. This suggests that in individuals with lower baseline WNT16 function (AA genotype), the repetitive loading of endurance running may not adequately compensate for reduced WNT16-mediated osteoclast suppression.

Practical Implications

Your genotype at rs3801387 provides insight into your cortical bone health trajectory, particularly your risk of non-vertebral fractures — those occurring at the hip, wrist, and other sites rich in cortical bone. Non-vertebral fractures cause enormous disability and mortality in older adults, yet existing osteoporosis treatments have only marginally reduced their incidence compared to the dramatic reductions seen for vertebral fractures. Understanding your genetic predisposition allows for earlier and more targeted preventive measures.

If you carry the AA genotype (higher risk), optimizing peak bone mass in early adulthood and minimizing bone loss thereafter becomes especially important. This means ensuring adequate calcium (1,000-1,200 mg/day) and vitamin D (800-1,000 IU/day for adults over 50) throughout life. Weight-bearing exercise ¹¹¹¹ Weight-bearing exercise is the single best intervention for cortical bone, as mechanical loading stimulates periosteal (outer surface) bone formation. For AA individuals who participate in high-volume endurance exercise, monitoring bone density and potentially incorporating resistance training may be particularly important.

Because WNT16 specifically affects cortical bone, standard DEXA scans of the hip and forearm (cortical-rich sites) are more informative than lumbar spine scans for monitoring your bone health trajectory. Consider establishing a baseline BMD measurement in your 40s if you have the AA genotype and additional risk factors (family history, low body weight, smoking, glucocorticoid use).

Interactions

Rs3801387 is in high linkage disequilibrium with other WNT16 variants including two missense SNPs (rs2707466 Thr>Ile and rs2908004 Gly>Arg) and rs7776725 in the adjacent FAM3C gene. These variants form haplotype blocks where the minor alleles generally cluster together and have a protective effect on BMD. When assessing bone health risk, consider that these variants act as a functional unit rather than independent factors.

WNT16 is part of the broader WNT signaling pathway, which includes other bone-related genes identified in GWAS such as LRP5, SOST, DKK1, and RANKL. However, WNT16's effect is uniquely cortical-specific, distinguishing it from pathway members that affect trabecular bone. This suggests that individuals with risk variants in both WNT16 and trabecular-affecting genes (like SOST) may face compounded fracture risk across multiple skeletal sites.

The interaction between rs3801387 genotype and vitamin D status deserves attention. A study in adolescents found multi-locus interactions between WNT16 rs3801387, vitamin D receptor (VDR), and vitamin D binding protein (VDBP) variants affecting serum vitamin D levels and bone quality ¹²¹² multi-locus interactions between WNT16 rs3801387, vitamin D receptor (VDR), and vitamin D binding protein (VDBP) variants affecting serum vitamin D levels and bone quality . While this finding needs replication, it suggests that individuals with the AA genotype may derive particular benefit from maintaining optimal vitamin D status, as the two systems appear to interact in regulating bone homeostasis.

Your heart muscle is held together by molecular anchors called desmosomes¹¹ desmosomes
protein complexes at the intercalated discs between cardiomyocytes — they transmit mechanical force and maintain cell-cell adhesion during every heartbeat. Desmoplakin (DSP) is the largest desmosomal protein and acts as the structural linchpin, connecting desmosomal cadherins at the cell surface to the intermediate filament cytoskeleton deep inside the cell. Without functional desmoplakin, cardiac cells cannot hold together under the mechanical stress of beating, leading to cell death, fibrofatty replacement of the myocardium, and the substrate for life-threatening arrhythmias.

The p.Arg160Ter mutation (c.478C>T, NM_004415.4) converts arginine at position 160 into a premature stop codon. The resulting truncated mRNA is targeted for nonsense-mediated decay²² nonsense-mediated decay
a cellular quality-control mechanism that degrades mRNA transcripts containing premature stop codons, preventing production of toxic truncated proteins — meaning the mutant allele produces essentially no functional desmoplakin protein. The result is haploinsufficiency: only one functional DSP allele remains to supply desmoplakin to every intercalated disc in every cardiomyocyte, leaving the heart structurally vulnerable.

This variant is classified Pathogenic/Likely pathogenic by 10 major genetic testing laboratories in ClinVar (VCV000044922), including GeneDx, Mayo Clinic Laboratories, Ambry Genetics, Labcorp Genetics, and the Stanford Center for Inherited Cardiovascular Disease — the highest possible evidence tier for rare disease variants.

The Mechanism

The p.Arg160Ter variant sits in the N-terminal head domain of DSP, upstream of the plakin domain and both spectrin repeat rod domains. A stop codon this early in the protein eliminates the entire functional architecture of desmoplakin. Recent experimental work³³ Recent experimental work
Smith et al., bioRxiv 2025 demonstrated that truncating DSP variants reduce DSP protein levels by 23–62% of normal in patient-derived cardiomyocytes. Under conditions of heightened contractile stress (simulated by endothelin-1 exposure), DSP-haploinsufficient cardiomyocytes showed 75% adhesion failure versus only 8% in controls. At baseline contractile load, adhesion was intact — explaining why carriers can appear clinically normal for decades before disease manifests during physiological or pathological stress (intense exercise, myocarditis, pregnancy).

The loss of desmosomal integrity triggers a cascade: cardiomyocytes detach and die, the immune system responds with inflammation, and myofibroblasts replace the lost muscle with fibrous and fatty tissue. This fibrofatty replacement creates late gadolinium enhancement⁴⁴ late gadolinium enhancement
a signal on cardiac MRI that indicates fibrous scar tissue, where gadolinium contrast agent persists because normal cardiomyocytes wash it out but scar tissue cannot visible on cardiac MRI and provides the electrical substrate for reentrant ventricular tachycardia and ventricular fibrillation.

The Evidence

DSP cardiomyopathy is now recognized as a distinct entity from classical arrhythmogenic right ventricular cardiomyopathy (ARVC). The landmark multicenter study by Smith et al., Circulation 2020⁵⁵ multicenter study by Smith et al., Circulation 2020
107 DSP and 81 PKP2 patients established that DSP mutations produce left-dominant disease in 55% of patients (versus 0% for PKP2), with LV late gadolinium enhancement in 40% and acute myocardial injury episodes — a myocarditis-like inflammatory flare — in 15%. Right ventricular cardiomyopathy was present in only 14% of DSP patients, meaning classical ARVC diagnostic criteria systematically miss DSP disease.

The largest outcomes study to date, Gasperetti et al., Eur Heart J 2025⁶⁶ Gasperetti et al., Eur Heart J 2025
800 patients with pathogenic DSP variants across 26 international institutions, found that 17.4% of DSP carriers experienced sustained ventricular arrhythmias (3.9%/year). Myocardial injury episodes — which 8.8% of carriers experienced — dramatically amplified subsequent risk: hazard ratio 2.394 for sustained VA and 5.064 for heart failure hospitalization.

For variants specifically triggering nonsense-mediated decay of both major DSP isoforms⁷⁷ nonsense-mediated decay of both major DSP isoforms
both DSP-I (ubiquitous isoform) and DSP-II (heart-enriched shorter isoform) are eliminated, maximizing the desmoplakin deficit in cardiac tissue — as p.Arg160Ter does — the Hoorntje et al., Circ Genom Precis Med 2023⁸⁸ Hoorntje et al., Circ Genom Precis Med 2023
170 DSP patients from an international cohort study found these individuals were dramatically overrepresented among clinically affected patients versus unaffected carriers (83.6% vs 16.4%, p<0.0001). Ventricular arrhythmia occurred in 33% of affected individuals in this cohort.

Genotype-phenotype analysis confirms that DSP non-missense variants (truncating, frameshift, splice site — all producing haploinsufficiency) carry substantially worse LV involvement than missense variants: LV dysfunction in 76.5% vs 10%⁹⁹ LV dysfunction in 76.5% vs 10% (p=0.001) and LV MRI involvement in 92% vs 22% (p=0.001).

Practical Actions

Carriers of pathogenic DSP variants require cardiomyopathy-specialist care, not routine cardiology follow-up. The standard ARVC Task Force Criteria are specifically less sensitive for DSP disease because they prioritize right ventricular findings — a cardiac MRI protocol looking for subepicardial LV late gadolinium enhancement is the key diagnostic test.

Risk stratification now has a validated clinical tool: the DSP risk score integrates female sex, NSVT history, PVC burden, LVEF, and RV function to stratify 5-year VA risk as low (<5%), intermediate (5–20%), or high (>20%). Patients in the high-risk category should be considered for ICD implantation regardless of whether they have had a documented arrhythmic event. Patients who experience a myocardial injury episode (acute troponin rise with myocarditis- like presentation) should be urgently re-evaluated, as this dramatically escalates risk.

First-degree family members (parents, siblings, children) each carry a 50% risk of inheriting this variant. Cascade genetic testing and cardiac imaging of all adult relatives is standard of care.

Interactions

The R160* variant eliminates both major DSP isoforms (DSP-I and DSP-II) through nonsense-mediated decay — this biallelic isoform impact distinguishes early-truncating variants from variants that spare the heart-enriched DSP-II isoform and may explain the particularly high clinical penetrance observed.

DSP haploinsufficiency can interact with physiological demands that stress desmosomal integrity: intense endurance or resistance exercise, viral myocarditis, and pregnancy have all been associated with acute myocardial injury episodes (inflammatory flares) in DSP cardiomyopathy carriers. These events — detectable by troponin elevation — independently predict subsequent arrhythmia and heart failure and should prompt immediate cardiac evaluation.

Among desmosomal gene variants, double-variant carriers (a pathogenic DSP variant plus a pathogenic variant in PKP2, DSG2, or DSC2) show substantially worse outcomes than single-variant carriers in the desmosomal cardiomyopathy cohort data. If additional desmosomal variants are identified on clinical genetic testing, this escalates management urgency.